close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Meiji Seika Pharma Co., Ltd.

News headline image
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma: First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Treatment of Psoriasis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today